Previous findings demonstrate that estrogen receptor beta (ERβ) is expressed in upwards of 20% of triple-negative tumors, and that ERβ functions as a tumor suppressor in triple-negative breast cancer models, it was of interest to determine if the tumor-suppressive effects of ERβ persisted in chemotherapy-resistant forms of the disease. The gene discussed is ESR2; the disease is neoplasm.